N-(6-(3-hydroxyphenyl)-1H-indazol-4-yl)cyclopropanecarboxamide | 1198804-22-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并吡唑类
• 英文名称: N-(6-(3-hydroxyphenyl)-1H-indazol-4-yl)cyclopropanecarboxamide
• 英文别名: N-[6-(3-hydroxyphenyl)-1H-indazol-4-yl]cyclopropanecarboxamide
• CAS: 1198804-22-6
• 化学式: C₁₇H₁₅N₃O₂
• 分子量: 293.325
• InChiKey: HCMVQAZIPLZCRY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  22
• 可旋转键数：
  3
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.18
• 拓扑面积：
  78
• 氢给体数：
  3
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  4-硝基-6-溴-1H-吲唑 在 盐酸 、 (1,1'-bis(diphenylphosphino)ferrocene)palladium(II) dichloride 、 palladium 10% on activated carbon 、 氢气 、 碳酸氢钠 、 N,N-二异丙基乙胺 、 三氟乙酸 作用下， 以 1,4-二氧六环 、 甲醇 、 二氯甲烷 、 水 、 乙酸乙酯 、 异丙醇 为溶剂， 30.0~150.0 ℃ 、3.0 MPa 条件下， 反应 3.67h， 生成 N-(6-(3-hydroxyphenyl)-1H-indazol-4-yl)cyclopropanecarboxamide
  参考文献：
  名称：

  From PIM1 to PI3Kδ via GSK3β: Target Hopping through the Kinome

  摘要：

  Selective inhibitors of phosphoinositide 3-kinase delta are of interest for the treatment of inflammatory diseases. Initial optimization of a 3-substituted indazole hit compound targeting the kinase PIM1 focused on improving selectivity over GSK3 beta through consideration of differences in the ATP binding pockets. Continued kinase cross-screening showed PI3K delta activity in a series of 4,6-disubstituted indazole compounds, and subsequent structure activity relationship exploration led to the discovery of an indole-containing lead compound as a potent PI3K delta inhibitor with selectivity over the other PI3K isoforms.

  DOI：

  10.1021/acsmedchemlett.7b00296

文献信息

• [EN] 4-CARBOXAMIDE INDAZOLE DERIVATIVES USEFUL AS INHIBITORS OF P13-KINASES<br/>[FR] DÉRIVÉS DE 4-CARBOXAMIDE INDAZOLE UTILES EN TANT QU'INHIBITEURS DE P13 KINASES
  申请人：GLAXO GROUP LTD

  公开号：WO2009147187A1

  公开（公告）日：2009-12-10

  The invention is directed to certain novel compounds. Specifically, the invention is directed to compounds of formula (I) and salts thereof. The compounds of the invention are inhibitors of P13-kinase activity.

  这项发明涉及某些新颖的化合物。具体来说，该发明涉及具有式(I)的化合物及其盐。该发明的化合物是P13-激酶活性的抑制剂。
• [EN] INDAZOLE DERIVATIVES FOR USE IN THE TREATMENT OF INFLUENZA VIRUS INFECTION<br/>[FR] DÉRIVÉS INDAZOLE À UTILISER DANS LE TRAITEMENT D'UNE INFECTION PAR LE VIRUS DE LA GRIPPE
  申请人：GLAXO GROUP LTD

  公开号：WO2012032065A1

  公开（公告）日：2012-03-15

  The present invention is directed to indazole compounds for use in the treatment or prevention of influenza virus infection.

  本发明涉及用于治疗或预防流感病毒感染的吲唑化合物。
• 4-CARBOXAMIDE INDAZOLE DERIVATIVES USEFUL AS INHIBITORS OF P13-KINASES
  申请人：Baldwin Ian Robert

  公开号：US20110112070A1

  公开（公告）日：2011-05-12

  The invention is directed to certain novel compounds. Specifically, the invention is directed to compounds of formula (I) and salts thereof. The compounds of the invention are inhibitors of P13-kinase activity.

  本发明涉及某些新颖化合物。具体而言，本发明涉及式(I)化合物及其盐。本发明的化合物是P13-激酶活性抑制剂。
• Novel Use
  申请人：Baldwin Ian Robert

  公开号：US20130165433A1

  公开（公告）日：2013-06-27

  The present invention is directed to compounds for use in the treatment or prevention of influenza virus infection.

  本发明涉及用于治疗或预防流感病毒感染的化合物。
• INDAZOLE DERIVATIVES FOR USE IN THE TREATMENT OF INFLUENZA VIRUS INFECTION
  申请人：GlaxoSmithKline Intellectual Property Development Limited

  公开号：EP2613781A1

  公开（公告）日：2013-07-17